BMO Capital on Sarepta (SRPT) Following Earlier Downgrade: 'we believe management could potentially turn the story around'
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated a Market Perform rating and $70.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
